We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Varian Medical Systems Acquires Calypso Medical Technologies

By HospiMedica International staff writers
Posted on 16 Oct 2011
Varian Medical Systems (Palo Alto, CA, USA) and Calypso Medical Technologies (Seattle, WA, USA) have announced a definitive agreement under which Varian will acquire Calypso, a privately-owned developer and supplier of specialized products and software for real-time tumor tracking and motion management during radiosurgery and radiotherapy. More...


The Calypso System features localization technology based on electromagnetic transponders that provide a way to continuously and accurately track target location, improving the precision of prostate cancer treatments. The transponders are implanted into the prostate or prostatic bed, and then tracked with the localization and tracking system so that radiotherapy and radiosurgery targeted beams can be precisely delivered to the tumors using medical linear accelerators, such as Varian's TrueBeam platform.

The acquisition includes Calypso Medical Technologies intellectual property portfolio with some 90 current or pending patents, and an investigational device exemption (IDE) approval by the US Food and Drug Administration (FDA) for a clinical study evaluating real-time tracking of lung cancer tumors during radiation delivery. It is expected that the Calypso business will be integrated into Varian's Oncology Systems segment, and will continue to operate in Seattle (WA, USA). Varian will pay approximately US$10 million for Calypso, plus potential earnouts based on unit sales of Calypso products achieved beyond thresholds over the next 30 months.

“With Calypso's technology, Varian will be able to offer cancer treatment centers real time, nonionizing tumor tracking tools for enhancing the precision of their treatments,” said Timothy Guertin, president and CEO of Varian Medical Systems. “These products are a perfect complement for Varian's motion management technology, including our TrueBeam platform, respiratory gating, and dynamic imaging tools for highly focused radiosurgery.”

“We are extremely gratified by the confidence and promise of this acquisition by Varian. It provides a tremendous opportunity to leverage our ‘GPS for the Body’ technology as broadly as possible,” said Edward Vertatschitsch, PhD, president and CEO of Calypso Medical. “Motion management is critical to accurately targeting the cancer so patients can experience the curative benefits of radiation therapy while protecting adjacent healthy tissue. We believe our real-time tracking capabilities will help to close the gap on this clinical challenge and I look forward to joining the Varian team to advance innovations in these areas.”

Related Links:
Varian Medical Systems
Calypso Medical Technologies



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Pediatric Mask
Respire SOFT
Surgical System
Stealth AXiS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image Cedit: Shutterstock

New Light-Activated Platform Advances Glioblastoma Surgery and Postoperative Treatment

Glioblastoma, an aggressive primary brain tumor, infiltrates healthy tissue and resists complete surgical removal. Residual microscopic disease and the blood–brain barrier limit the effectiveness of adjuvant... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.